Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and benefit of nivolumab, ipilimumab or
the combination of nivolumab with ipilimumab given after bone marrow transplant for patients
with acute myelogenous leukemia and myelodysplastic syndrome.
Phase:
Phase 1
Details
Lead Sponsor:
Hackensack Meridian Health Hackensack University Medical Center